Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.78 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.66 |
| ▸ | CTSL | P07711 | 6/20 | 0.65 |
| ▸ | CTSB | P07858 | 3/20 | 0.65 |
| ▸ | CTSS | P25774 | 2/20 | 0.65 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5598105 | 1.00 | CTSK (0.78) | CTSKCAPN1CTSLCTSBCTSS | |
| SCHEMBL30091425 | 0.96 | CTSK (0.72) | CTSKCAPN1CTSLCTSBCTSS | |
| SCHEMBL8744667 | 0.93 | CTSK (0.68) | CTSKCAPN1CTSLCTSBCTSS | |
| SCHEMBL8744665 | 0.93 | CTSK (0.68) | CTSKCAPN1CTSLCTSBCTSS | |
| SCHEMBL25406813 | 0.92 | CTSK (0.77) | CTSKCAPN1CTSLCTSBCTSS | |
| SCHEMBL4872585 | 0.92 | CTSK (0.77) | CTSKCAPN1CTSLCTSBCTSS | |
| SCHEMBL20770085 | 0.92 | CTSK (0.77) | CTSKCAPN1CTSLCTSBCTSS | |
| SCHEMBL14148467 | 0.92 | CTSK (0.77) | CTSKCAPN1CTSLCTSBCTSS | |
| SCHEMBL8823918 | 0.92 | CTSK (0.77) | CTSKCAPN1CTSLCTSBCTSS | |
| SCHEMBL2930262 | 0.92 | CTSK (0.77) | CTSKCAPN1CTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542682-A4 | NOVEL INHIBITORS OF UBIQUITIN ISOPEPTIDASES | UNIV UTAH RES FOUND (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20060106099-A1 | Novel inhibitors of ubiquitin isopeptidases | UNIVERSITY OF UTAH | 2006-05-18 | — | — | US | disclosed |
| EP-1542682-A2 | NOVEL INHIBITORS OF UBIQUITIN ISOPEPTIDASES | University of Utah Research Foundation (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004009023-A2 | NOVEL INHIBITORS OF UBIQUITIN ISOPEPTIDASES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106099-A1 | Novel inhibitors of ubiquitin isopeptidases | TP53, MDM2, UCHL1 | CTSK 1504/4885CAPN1 201/4885CTSL 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.